Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025 bởi

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

30 May 2025

Growth hormone therapy appears to boost height and growth rate in girls with Turner Syndrome (TS) or growth hormone deficiency (GHD), with pronounced effect seen in the first year of treatment, according to a case-control study.

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

30 May 2025

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

30 May 2025 bởi

Women with opioid use disorder (OUD) treated with buprenorphine during pregnancy had significantly lower rates of adverse maternal and infant outcomes than those who did not receive treatment, according to a study presented at PAS 2025.

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

30 May 2025

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

29 May 2025

In critically ill patients with moderate-to-severe acute respiratory distress syndrome (ARDS), inhaled sedation with sevoflurane may lead to fewer ventilator-free days at day 28 and lower 90-day survival compared with sedation with propofol, according to the results of the phase III SESAR study.

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

29 May 2025

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

29 May 2025 bởi

IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

29 May 2025

Original New Drug Application Approvals by US FDA (16-30 April 2025)

29 May 2025

New drug applications approved by US FDA as of 16-30 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 April 2025)

29 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

New drug applications approved by US FDA as of 1-15 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

10-year data reflect teduglutide efficacy for SBS-IF

28 May 2025 bởi

An interim analysis of a real-world study reporting up to 10 years of follow-up data shows that teduglutide, a human glucagon-like peptide-2 analogue, can provide long-term reductions in parenteral nutrition and/or intravenous fluid (PN/IV) requirements and shorter time to achieve enteral autonomy in adults with short bowel syndrome-associated intestinal failure (SBS-IF).

10-year data reflect teduglutide efficacy for SBS-IF

28 May 2025

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

28 May 2025

In the treatment of adults with hospital-associated (HABP) or ventilator-associated bacterial pneumonia (VABP), the β-lactam/β-lactamase inhibitor combination imipenem/cilastatin/relebactam appears to be as good as piperacillin/tazobactam, with similar safety profiles, according to a phase III trial.

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

28 May 2025

BP medication timing: Bedtime or daytime, the effect’s the same

27 May 2025 bởi

For adults with hypertension being treated in the primary care setting, taking their blood pressure (BP)-lowering medications at bedtime is safe but confers no additional cardiovascular protection as opposed to taking them in the morning, according to the results of the BedMed trial.

BP medication timing: Bedtime or daytime, the effect’s the same

27 May 2025

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

Original New Drug Application Approvals by US FDA (16-30 April 2025)

Original New Drug Application Approvals by US FDA (16-30 April 2025)

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

10-year data reflect teduglutide efficacy for SBS-IF

10-year data reflect teduglutide efficacy for SBS-IF

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

BP medication timing: Bedtime or daytime, the effect’s the same

BP medication timing: Bedtime or daytime, the effect’s the same